keyword
Keywords Cardiovascular disease after a...

Cardiovascular disease after aromatase

https://read.qxmd.com/read/38453587/-effects-of-extended-aromatase-inhibitors-in-women-with-hormone-dependent-breast-cancer-who-have-already-received-five-years-of-adjuvant-hormone-therapy-a-systematic-review-and-meta-analysis
#1
JOURNAL ARTICLE
Kossi Clément Trenou, Miceline Mésidor, Caroline Diorio, Aida Eslami, Denis Talbot
INTRODUCTION: Evaluating the benefits and risks of prolonged hormonal treatment with aromatase inhibitors (AIs) for treating hormone-dependent breast cancer. METHODS: A systematic review and meta-analysis was conducted. Studies reporting on randomized clinical trials concerning prolongating hormonal therapy with AIs as compared to a placebo or no prolongation, after an initial five years of hormonal therapy, were eligible. RESULTS: Seven clinical trials were included...
March 6, 2024: Bulletin du Cancer
https://read.qxmd.com/read/37890547/cardiovascular-impact-of-near-complete-estrogen-deprivation-in-premenopausal-women-with-breast-cancer-the-crown-study
#2
JOURNAL ARTICLE
Alexandra Thomas, Nathaniel S O'Connell, Emily Douglas, Sarah Hatcher, Carolyn J Park, Susan Dent, Katherine Ansley, Igor Klem, Rani Bansal, Kelly Westbrook, W Gregory Hundley, Wendy Bottinor, Mary Helen Hackney, Karl M Richardson, Sherona R Sirkisoon, Ralph B D'Agostino, Jennifer H Jordan
Survival with operable breast cancer has improved markedly in recent decades, however, treatment-related cardiovascular toxicities threaten to offset these gains. Ovarian function suppression paired with aromatase inhibition, for premenopausal women with hormone receptor (HR)-positive breast cancer, is a newer widely adopted therapy with the potential for significant long-term cardiovascular toxicity. Abrupt estrogen deprivation for non-cancer reasons is associated with accelerated coronary artery disease. Women with breast cancer treated with aromatase inhibition in addition to ovarian function suppression experience a dual hit with regards to estrogen exposure...
October 25, 2023: American Heart Journal
https://read.qxmd.com/read/37888299/snp-of-aromatase-predict-long-term-survival-and-aromatase-inhibitor-toxicity-in-patients-with-early-breast-cancer-a-biomarker-analysis-of-the-gim4-and-gim5-trials
#3
JOURNAL ARTICLE
Benedetta Conte, Luca Boni, Giancarlo Bisagni, Antonio Durando, Giovanni Sanna, Stefania Gori, Ornella Garrone, Stefano Tamberi, Sabino De Placido, Francesco Schettini, Antonio Pazzola, Riccardo Ponzone, Filippo Montemurro, Gianluigi Lunardi, Rosario Notaro, Maria De Angioletti, Anna Turletti, Mauro Mansutti, Fabio Puglisi, Antonio Frassoldati, Mauro Porpiglia, Alessandra Fabi, Daniele Generali, Giovanni Scognamiglio, Maura Rossi, Fara Brasó-Maristany, Aleix Prat, Barbara Cardinali, Patrizia Piccioli, Martina Serra, Sonia Lastraioli, Claudia Bighin, Francesca Poggio, Matteo Lambertini, Lucia Del Mastro
PURPOSE: In estrogen receptor-positive (ER+) breast cancer, single-nucleotide polymorphisms (SNP) in the aromatase gene might affect aromatase inhibitors (AI) metabolism and efficacy. Here, we assessed the impact of SNP on prognosis and toxicity of patients receiving adjuvant letrozole. EXPERIMENTAL DESIGN: We enrolled 886 postmenopausal patients in the study. They were treated with letrozole for 2 to 5 years after taking tamoxifen for 2 to 6 years, continuing until they completed 5 to 10 years of therapy...
December 15, 2023: Clinical Cancer Research
https://read.qxmd.com/read/37779374/male-specific-consequences-of-obesity-functional-hypogonadism-and-fertility-disorders
#4
JOURNAL ARTICLE
Michał Rabijewski
Obesity is currently one of the most serious public health problems which affects up to 30-40% of the population, and its prevalence is higher in men than in women. Complications of obesity include atherosclerosis, cardiovascular diseases, and type 2 diabetes mellitus, but it also has a negative impact on the hormonal system and fertility. The hormonal consequences of excess body fat in men are functional hypogonadism, which not only causes clinical symptoms of testosterone deficiency, but is also a risk factor for obesity (a vicious circle mechanism)...
October 2, 2023: Endokrynologia Polska
https://read.qxmd.com/read/37258098/a-narrative-review-of-heart-failure-with-preserved-ejection-fraction-in-breast-cancer-survivors
#5
REVIEW
Vidhushei Yogeswaran, Elena Wadden, Warren Szewczyk, Ana Barac, Michael S Simon, Charles Eaton, Richard K Cheng, Kerryn W Reding
Advances in breast cancer (BC) treatment have contributed to improved survival, but BC survivors experience significant short-term and long-term cardiovascular mortality and morbidity, including an elevated risk of heart failure with preserved ejection fraction (HFpEF). Most research has focused on HF with reduced ejection fraction (HFrEF) after BC; however, recent studies suggest HFpEF is the more prevalent subtype after BC and is associated with substantial health burden. The increased HFpEF risk observed in BC survivors may be explained by treatment-related toxicity and by shared risk factors that heighten risk for both BC and HFpEF...
July 27, 2023: Heart
https://read.qxmd.com/read/37066265/endothelial-dysfunction-in-breast-cancer-survivors-on-aromatase-inhibitors-changes-over-time
#6
Adnan Shaaban, Ashley Petersen, Heather Beckwith, Natalia Florea, David A Potter, Douglas Yee, Rachel I Vogel, Daniel Duprez, Anne H Blaes
Background Aromatase inhibitors (AIs) are recommended as adjuvant treatment for estrogen-receptor positive breast carcinoma in postmenopausal women. Studies demonstrate mixed results as to the impact of AIs on cardiovascular (CV) events and overall survival. With the increasing number of pre- and postmenopausal women on AIs for five to ten years, understanding the long-term impact of AIs on blood vessels and CV risk in cancer survivors is vital. Methods A single arm longitudinal study of 14 postmenopausal women with ER+ breast cancer prescribed adjuvant AIs at the University of Minnesota...
April 3, 2023: Research Square
https://read.qxmd.com/read/36826103/risk-of-cardiovascular-events-and-lipid-profile-change-in-patients-with-breast-cancer-taking-aromatase-inhibitor-a-systematic-review-and-meta-analysis
#7
JOURNAL ARTICLE
Jeong-Ju Yoo, Eun-Ae Jung, Zisun Kim, Bo-Yeon Kim
Cardiovascular disease (CVD) is one of the most common comorbidities in breast cancer survivors. Recently, the target population and treatment period for aromatase inhibitor (AI) treatment in breast cancer patients has been expanding. However, information on adverse CVD events from the long-term use of AI is still lacking. The aim of this study was to investigate the CVD side effects of AI treatment and to evaluate the changes in lipid profile during AI treatment. A systematic search of PubMed (Medline), EMBASE, and Cochrane Library databases reporting on cardiovascular outcomes or lipid profiles change in adult female breast cancer patients (>19 years old) with AI was performed...
February 2, 2023: Current Oncology
https://read.qxmd.com/read/36250658/effects-of-endocrine-therapy-on-cardiovascular-diseases-and-type-2-diabetes-among-breast-cancer-survivors-the-national-health-insurance-service-database-of-korea
#8
JOURNAL ARTICLE
Ji-Eun Kim, Jaesung Choi, JooYong Park, Wonshik Han, Daehee Kang, Ji-Yeob Choi
Background Although endocrine therapy is an effective treatment for breast cancer, its antiestrogen effects are associated with increased risks of cardiovascular diseases and type 2 diabetes. This study aimed to investigate the association between endocrine therapy and the risk of cardiovascular diseases and type 2 diabetes among breast cancer survivors in Korea, in consideration of various age groups. Methods and Results In the National Health Insurance Service database of Korea, a total of 133 171 patients with breast cancer aged ≥20 years were included in the current study...
October 17, 2022: Journal of the American Heart Association
https://read.qxmd.com/read/36181605/adjuvant-aromatase-inhibitor-therapy-and-early-markers-for-cardiovascular-disease-in-breast-cancer-survivors
#9
JOURNAL ARTICLE
Annemiek van Ommen-Nijhof, Judy N Jacobse, Lars C Steggink, Joop D Lefrandt, Jourik A Gietema, Flora E van Leeuwen, Michael Schaapveld, Gabe S Sonke
PURPOSE: Aromatase inhibitors (AIs) are an important component of the adjuvant treatment of hormone receptor positive breast cancer (BC) but concerns regarding their cardiovascular safety remain. In this cross-sectional study nested in a breast cancer cohort, we investigated the association between AI exposure and early markers for cardiovascular disease in BC survivors. METHODS: The study population consisted of 569 women, who were 5-7 years (n = 277) or 10-12 years (n = 292) after BC diagnosis...
October 1, 2022: Breast Cancer Research and Treatment
https://read.qxmd.com/read/35900340/aromatase-inhibition-increases-blood-pressure-and-markers-of-renal-injury-in-female-rats
#10
JOURNAL ARTICLE
Rawan N Almutlaq, Annie E Newell-Fugate, Louise Christine Evans, Huma Fatima, Eman Y Gohar
Aromatase is a monooxygenase that catalyzes the rate-limiting step of estrogen biosynthesis from androgens. Aromatase inhibitors are widely used for treatment of patients with breast cancer. However, the effects of aromatase inhibitors on cardiovascular and renal health in females are understudied. Given that estrogen is protective against cardiovascular and kidney diseases, we hypothesized that aromatase inhibition elevates blood pressure and induces kidney injury in female Sprague Dawley rats. Twelve-week-old female rats were implanted with radio-telemetry transmitters to continuously monitor blood pressure...
July 28, 2022: American Journal of Physiology. Renal Physiology
https://read.qxmd.com/read/35753212/preventing-late-recurrence-in-hormone-receptor-positive-early-breast-cancer-a-review
#11
REVIEW
Nicolò Matteo Luca Battisti, Ian E Smith
Late recurrences are a key challenge for patients with early-stage oestrogen receptor-positive breast cancer, with the risk of disease relapse continuing steadily from 5 to more than 20 years after diagnosis. Five years of adjuvant endocrine therapy with tamoxifen or an aromatase inhibitor was shown many years ago to improve survival. More recently, the trials of extended adjuvant endocrine therapy for more than 5 years have shown a further small gain, but with an associated small risk of increased long-term toxicity including bone loss, cardiovascular impairment and impaired quality of life...
September 2022: European Journal of Cancer
https://read.qxmd.com/read/35585836/the-effect-of-exercise-training-on-endothelial-function-in-postmenopausal-women-with-breast-cancer-under-aromatase-inhibitor-therapy
#12
JOURNAL ARTICLE
Barbara Mayr, Bernhard Reich, Richard Greil, Josef Niebauer
BACKGROUND: Breast cancer is the leading non-cardiovascular cause of death in women. In endocrine receptor positive women, aromatase inhibitors (AI) are the therapy of choice despite the fact that a decrease in systemic estrogen levels may result in endothelial dysfunction and eventually in cardiovascular disease. In this study, we assessed whether exercise training (ET), which has repeatedly shown to lead to an improvement of endothelial dysfunction, will also exert this effect in postmenopausal women with AI treated breast cancer...
May 18, 2022: Cancer Medicine
https://read.qxmd.com/read/35334418/effect-of-concomitant-statin-treatment-in-postmenopausal-patients-with-hormone-receptor-positive-early-stage-breast-cancer-receiving-adjuvant-denosumab-or-placebo-a-post-hoc-analysis-of-abcsg-18
#13
JOURNAL ARTICLE
C Minichsdorfer, T Fuereder, M Leutner, C F Singer, S Kacerovsky-Strobl, D Egle, R Greil, M Balic, F Fitzal, G Pfeiler, S Frantal, R Bartsch, M Gnant
BACKGROUND: Statins are cholesterol-lowering drugs prescribed for the prevention and treatment of cardiovascular disease. Moreover, statins may possess anticancer properties and interact with receptor activator of nuclear factor κB ligand expression. We aimed at evaluating a hypothetical synergistic effect of statins with denosumab in early-stage breast cancer (BC) patients from the Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 18. PATIENTS AND METHODS: ABCSG-18 (NCT00556374) is a prospective, randomized, double-blind, phase III study; postmenopausal patients with hormone receptor-positive BC receiving a nonsteroidal aromatase inhibitor were randomly assigned to denosumab or placebo...
March 22, 2022: ESMO Open
https://read.qxmd.com/read/34825307/predicting-the-clinical-outcomes-and-benefit-from-letrozole-after-5-years-of-treatment-with-aromatase-inhibitors-for-early-breast-cancer-analysis-from-cctg-ma-17r
#14
RANDOMIZED CONTROLLED TRIAL
Yapeng Li, Xueying Zheng, Dongsheng Tu, James N Ingle, Paul E Goss, Wendy R Parulekar, Guoyou Qin
PURPOSE: Women with hormone receptor positive breast cancer may receive 5 years of treatment with aromatase inhibitors but the magnitude of benefit was relatively small. Our goal was to develop a tool for identification of women with limited treatment benefit. METHODS: Regression analyses were applied to women treated by placebo in CCTG MA.17R trial (NCT00754845) to identify important prognostic factors associated with distant recurrence and develop a nomogram for predicting 5-year likelihood of distant recurrence, which was internally validated using bootstrap resampling method...
February 2022: Breast Cancer Research and Treatment
https://read.qxmd.com/read/34661247/low-testosterone-levels-and-high-estradiol-to-testosterone-ratio-are-associated-with-hyperinflammatory-state-and-mortality-in-hospitalized-men-with-covid-19
#15
JOURNAL ARTICLE
M Infante, M Pieri, S Lupisella, L D'Amore, S Bernardini, A Fabbri, M Iannetta, M Andreoni, M Morello
OBJECTIVE: Evidence supports a sex disparity in clinical outcomes of COVID-19 patients, with men exhibiting higher mortality rates compared to women. We aimed to test the correlation between serum levels of sex hormones [total testosterone, estradiol (E2), estradiol to testosterone (E2/T) ratio, progesterone), prolactin and 25-hydroxyvitamin D [25(OH)D] and markers of inflammation, coagulation and sepsis at admission in hospitalized men with COVID-19. PATIENTS AND METHODS: We conducted an exploratory retrospective study including symptomatic men with confirmed SARS-CoV-2 infection who were consecutively admitted to our Institution between April 1 and May 31, 2020...
October 2021: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/33852527/cardiac-and-brainstem-neuroinflammatory-pathways-account-for-androgenic-incitement-of-cardiovascular-and-autonomic-manifestations-in-endotoxic-male-rats
#16
JOURNAL ARTICLE
Marwa Y Sallam, Sahar M El-Gowilly, Mahmoud M El-Mas
Inconsistent reports are available on the role of testosterone in end-organ damage caused by endotoxemia. Here, pharmacologic, surgical, and molecular studies were employed to assess the testosterone modulation of cardiovascular, autonomic, and peripheral and central inflammatory derangements caused by endotoxemia. Studies were performed in conscious male rats preinstrumented with femoral indwelling catheters for the measurement of blood pressure and subjected to castration or pharmacologic interventions that interrupt the biosynthetic cascade of testosterone...
May 1, 2021: Journal of Cardiovascular Pharmacology
https://read.qxmd.com/read/33159633/cumulative-incidence-of-cardiovascular-events-under-tamoxifen-and-letrozole-alone-and-in-sequence-a-report-from-the-big-1-98-trial
#17
RANDOMIZED CONTROLLED TRIAL
Manuela Rabaglio, Zhuoxin Sun, Rudolf Maibach, Anita Giobbie-Hurder, Bent Ejlertsen, Vernon J Harvey, Patrick Neven, István Láng, Hervé Bonnefoi, Andrew Wardley, Barbara Ruepp, Monica Castiglione, Alan S Coates, Richard D Gelber, Aron Goldhirsch, Marco Colleoni, Beat Thürlimann, Meredith M Regan
BACKGROUND: Compared to tamoxifen, adjuvant treatment with aromatase inhibitors improves disease outcomes of postmenopausal women with hormone receptor-positive early breast cancer. In the international, randomized, double-blind BIG 1-98 trial, 8010 women were randomized to receive tamoxifen, letrozole, or sequential use of the agents for 5 years. With a focus on switching between agents, we investigated cardiovascular events over the entire 5-year treatment period. METHODS: Of the 6182 patients enrolled, 6144 started trial treatment and were included in this analysis...
February 2021: Breast Cancer Research and Treatment
https://read.qxmd.com/read/32964358/risk-of-heart-failure-after-systemic-treatment-for-early-breast-cancer-results-of-a-cohort-study
#18
MULTICENTER STUDY
Judy N Jacobse, Michael Schaapveld, Naomi B Boekel, Maartje J Hooning, Agnes Jager, Margreet H A Baaijens, Michael Hauptmann, Nicola S Russell, Emiel J T Rutgers, Berthe M P Aleman, Gabe S Sonke, Flora E van Leeuwen
PURPOSE: Anthracyclines and trastuzumab can increase the risk of heart failure (HF), but long-term cardiotoxicity data in breast cancer (BC) patients treated at younger ages are limited. Furthermore, it is unknown whether aromatase inhibitors are associated with HF risk. METHODS: HF risk was studied in a multicenter cohort of BC survivors treated during 2000-2009, at age < 61 years. Information on treatment and cardiovascular disease incidence was collected through medical records, general practitioners and cardiologists...
January 2021: Breast Cancer Research and Treatment
https://read.qxmd.com/read/32730287/risk-of-fatty-liver-after-long-term-use-of-tamoxifen-in-patients-with-breast-cancer
#19
JOURNAL ARTICLE
Jeong-Ju Yoo, Yong Seok Lim, Min Sung Kim, Bora Lee, Bo-Yeon Kim, Zisun Kim, Ji Eun Lee, Min Hee Lee, Sang Gyune Kim, Young Seok Kim
BACKGROUND: Few studies report the effects of tamoxifen intake and the occurrence of de novo fatty liver and the deterioration of existing fatty liver. The aim of this study was to investigate the effects of tamoxifen on fatty change of liver over time and also the impact of fatty liver on the prognosis of patients with breast cancer. METHODS: This was a single-center, retrospective study of patients who were diagnosed with primary breast cancer from January 2007 to July 2017...
2020: PloS One
https://read.qxmd.com/read/32488391/evolution-in-the-risk-of-adverse-events-of-adjuvant-endocrine-therapy-in-postmenopausal-women-with-early-stage-breast-cancer
#20
REVIEW
Daniel Reinhorn, Rinat Yerushalmi, Assaf Moore, Alexandra Desnoyers, Ramy R Saleh, Eitan Amir, Hadar Goldvaser
BACKGROUND: Adjuvant endocrine therapy is a gold standard in early-stage, hormone receptor positive breast cancer. In postmenopausal women, aromatase inhibitors (AIs) are associated with improved outcome compared to tamoxifen monotherapy. Differences in the toxicity profiles of these drugs are described; however, little is known about whether the risk of adverse events changes over time. METHODS: Sequential reports of large, randomized, adjuvant endocrine therapy trials comparing AIs to tamoxifen were reviewed...
July 2020: Breast Cancer Research and Treatment
keyword
keyword
101427
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.